| Patient | Theodore Roosevelt |
|---|---|
| Date of birth | 2002-10-27 |
| Identifiers | MRN HR-NI012-SYN; SSN (made up) 000-12-6157 |
| Document date | 2026-04-06 |
| Author | Amos Kettering, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week asthma review after starting maintenance-and-reliever therapy. [S]
Mr. Roosevelt returns four weeks after changing from albuterol alone to budesonide-formoterol two inhalations twice daily plus one as needed. He is much better: daytime symptoms on two or three days a week instead of most days, night waking once in four weeks, and he finishes his boxing rounds. He has used 4 to 6 as-needed inhalations a week, mostly before training. The dose counter matches about 90 percent of maintenance doses; he missed some evening doses on late session nights. His home peak flow ranges from 560 to 600 L/min. He has had no hoarseness or sore mouth. He still hopes training alone will eventually be enough. He saw the pulmonologist this morning. [S]
| Element | Detail |
|---|---|
| Interval change | Symptoms two or three days a week; night waking once in four weeks |
| Reliever use | 4 to 6 as-needed inhalations a week, mostly before training |
| Adherence | About 90 percent of maintenance doses by dose counter; evening doses missed on late nights |
| Home peak flow | 560 to 600 L/min |
| Medication tolerance | No hoarseness, sore mouth, or tremor |
| Patient concern | Would prefer to rely on exercise rather than medicine |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Mild wheeze on two or three days a week; no cough at night in the last three weeks |
| Ears, nose, mouth, and throat | Negative | No nasal blockage, sneezing, hoarseness, or sore mouth |
| Gastrointestinal | Negative | No heartburn or reflux |
| Psychiatric | Negative | Mood good; sleeping better |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two inhalations as needed for wheeze (bought after an urgent care visit; used most days before intake) | Two inhalations every 4 hours as needed | Respiratory tract route | 2025-12-15 to 2026-03-09 | stopped | S |
| Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenance | Two inhalations twice daily, with a spacer, rinsing the mouth afterwards | Respiratory tract route | 2026-03-09 | active | S |
| Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in total | One inhalation as needed, repeated after a few minutes if needed; maximum 12 inhalations a day including maintenance doses | Respiratory tract route | 2026-03-09 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-06 | Body height | 175 | cm | S |
| 2026-04-06 | Body weight | 72.4 | kg | S |
| 2026-04-06 | Body mass index (BMI) [Ratio] | 23.6 | kg/m2 | S |
| 2026-04-06 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-04-06 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-04-06 | Heart rate | 76 | /min | S |
| 2026-04-06 | Respiratory rate | 16 | /min | S |
| 2026-04-06 | Body temperature | 36.7 | Cel | S |
| 2026-04-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-06 | Total score [ACT] | 18 | {score} | S | ||
| 2026-04-06 | Fractional concentration of exhaled nitric oxide | 46 | [ppb] | <=25 [ppb] | High | S |
| 2026-04-06 | Eosinophils [#/volume] in Blood by Automated count | 0.42 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 2026-04-06 | IgE [Units/volume] in Serum or Plasma | 260 | [IU]/mL | <=100 [IU]/mL | High | S |
| 2026-04-06 | European house dust mite IgE Ab [Units/volume] in Serum | 8.4 | k[IU]/L | <=0.35 k[IU]/L | High | S |
Vital signs recorded on 2026-04-06; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, talking easily |
| Nose | Normal mucosa; no polyps |
| Mouth | No thrush |
| Lungs | A few end-expiratory wheezes on forced expiration only |
| Inhaler technique | With his own inhaler and spacer: did not breathe out before the dose and held his breath for only two seconds; corrected, and demonstrated back correctly |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Moderate persistent asthma, uncontrolled at intake, with reversible airflow obstruction on spirometry; synthetic modern diagnosis linked to his documented lifelong asthma | active | confirmed | J45.40 | S — Synthetic modern classification confirmed by spirometry; the historical asthma is D and its persistence into adulthood is R. |
| Myopia, both eyes, corrected with glasses since boyhood | active | confirmed | H52.13 | S — Synthetic modern entry linked to his documented near-sightedness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 18, up from 13; not yet at the target of 20 |
| Examination | Inhaler technique with his own device | Every visit | Completed today | Two critical errors corrected; correct on repeat demonstration |
| Medication safety | Adherence and reliever use | Every visit | Completed today | About 90 percent adherence; 4 to 6 as-needed inhalations a week |
| Survey | Exacerbation history | Every visit | Completed today | None since starting controller therapy |
| Self-management | Trigger and exposure review, smoking and vaping status | Every visit; detailed at diagnosis and yearly | Completed today | Colds and dust are his triggers; never smoker; no vaping; no occupational exposure |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Reviewed; peak-flow zones will be reset once his personal best is confirmed |
| Laboratory | FeNO, blood eosinophils, total IgE, and specific IgE | As indicated: diagnostic uncertainty, phenotyping, allergen-directed treatment | Completed today | Ordered by pulmonology: FeNO 46 ppb, eosinophils 0.42 x10³/µL, total IgE 260 IU/mL, dust mite IgE 8.4 kU/L |
| Referral | Pulmonology consultation | At diagnosis of uncontrolled persistent asthma | Completed today | Seen today; diagnosis confirmed and type 2 phenotype identified |
| Examination | Spirometry | At diagnosis, 3 to 6 months after stabilization, then every 1 to 2 years | Due | Baseline at intake; repeat at the three-month review |
| Examination | Home peak flow monitoring | Daily or with symptoms for moderate to severe asthma | Completed today | Readings 560 to 600 L/min; personal best still being established |
| Survey | Step-up or step-down assessment | Every visit | Completed today | Stay at Step 4; correct technique and adherence before any change |
| Examination | Comorbidity surveillance: rhinitis and sinus disease, reflux, obesity, sleep apnea, vocal cord dysfunction, anxiety and depression | At diagnosis and yearly | Completed today | None found; BMI 23.6; PHQ-2 0 at intake; no stridor or sudden throat tightness to suggest vocal cord dysfunction |
| Medication safety | Vaccination status | Yearly | Completed today | PCV20 given today; influenza vaccine this past autumn |
| Imaging | Chest radiograph or CT | Only for atypical features or suspected complication | Not indicated | Typical asthma with reversible obstruction |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026)
Follow-up: Asthma review with spirometry in two months, three months after starting controller therapy. Next scheduled visit 2026-06-08: three-month asthma review with repeat spirometry. [S]